New York Influenza Center of Excellence, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 609, Rochester, NY 14642, USA. felix
Vaccine. 2012 Jun 29;30(31):4606-16. doi: 10.1016/j.vaccine.2012.05.005. Epub 2012 May 15.
Antibodies directed against the influenza hemagglutinin (HA) protein largely mediate virus neutralization and confer protection against infection. Consequently, many studies and assays of influenza vaccines are focused on HA-specific immune responses. Recombinant HA (rHA) proteins can be produced in a number of protein expression and cell culture systems. These range from baculovirus infection of insect cell cultures, to transient transfection of plants, to stably transfected human cell lines. Furthermore, the rHA proteins may contain genetic modifications, such as histidine tags or trimerization domains, intended to ease purification or enhance protein stability. However, no systematic study of these different forms of the HA protein have been conducted. It is not clear which, if any, of these different protein expression systems or structural modifications improve or diminish the biological behavior of the proteins as immunogens or antigens in immune assays. Therefore we set out to perform systematic evaluation of rHA produced in different proteins expression systems and with varied modifications. Five rHA proteins based on recent strains of seasonal influenza A and five based on influenza B HA were kindly provided by the Biodefense and Emerging Infections Reagent Repository (BEIR). These proteins were evaluated in a combination of biochemical and structural assays, in vitro humoral and cellular immune assays, and in an animal vaccination model. Marked differences in the behavior of the individual proteins was evident suggesting that they are not equal when being used to detect an immune response. They were, nevertheless, similar at eliciting neutralizing antibody responses.
针对流感血凝素 (HA) 蛋白的抗体在很大程度上介导病毒中和作用,并提供针对感染的保护。因此,许多流感疫苗的研究和检测都集中在 HA 特异性免疫反应上。重组 HA(rHA)蛋白可以在许多蛋白表达和细胞培养系统中产生。这些系统包括杆状病毒感染昆虫细胞培养物、植物瞬时转染、稳定转染的人细胞系。此外,rHA 蛋白可能包含遗传修饰,如组氨酸标签或三聚化结构域,旨在便于纯化或增强蛋白稳定性。然而,尚未对这些 HA 蛋白的不同形式进行系统研究。目前尚不清楚这些不同的蛋白表达系统或结构修饰中的任何一种是否可以改善或降低蛋白作为免疫原或抗原在免疫检测中的生物学行为。因此,我们着手对不同蛋白表达系统和不同修饰形式产生的 rHA 进行系统评估。五种基于近期季节性 A 型流感和五种基于 B 型流感 HA 的 rHA 蛋白由生物防御和新兴传染病试剂库 (BEIR) 提供。这些蛋白通过生化和结构检测、体外体液和细胞免疫检测以及动物疫苗接种模型进行了评估。单个蛋白行为的明显差异表明,在用于检测免疫反应时,它们并不平等。然而,它们在诱导中和抗体反应方面是相似的。